Clinical trial
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
NCT00468182 · Rutgers, The State University of New Jersey, Other · Completed
Key facts
| NCT number | NCT00468182 |
|---|---|
| Title | Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis |
| Official title | Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis |
| Lead sponsor | Rutgers, The State University of New Jersey, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon-beta 1b (Betaseron) |
| Enrollment | 24 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | May 2, 2007 |
| Last update posted | May 7, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: